Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/94434
Title: | Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications |
Authors: | Godman, Brian Hill, Andrew Simoens, Steven Selke, Gisbert Krulichová, Iva Selke Zampirolli Dias, Carolina Martin, Antony P. Oortwijn, Wija Timoney, Angela Gustafsson, Lars L. Voncina, Luka Kwon, Hye-Young Gulbinovic, Jolanta Gotham, Dzintars Wale, Janet Cristina Da Silva, Wânia Bochenek, Tomasz Allocati, Eleonora Kurdi, Amanj Ogunleye, Olayinka O. Meyer, Johanna C. Hoxha, Iris Malaj, Admir Hierländer, Christian Sauermann, Robert Hamelinck, Wouter Petrova, Guenka Laius, Ott Langner, Irene Yfantopoulos, John Joppi, Roberta Jakupi, Arianit Greiciute-Kuprijanov, Ieva Vella Bonanno, Patricia Piepenbrink, JF (Hans) Valk, Vincent de Wladysiuk, Magdalene Marković-Peković, Vanda Mardare, Ileana Fürst, Jurij Tomek, Dominik Cortadellas, Mercè Obach Zara, Corinne Pontes, Caridad McTaggart, Stuart Laba, Tracey-Lea Melien, Øyvind Wong-Rieger, Durhane Bae, SeungJin Hill, Ruaraidh |
Keywords: | Cancer -- Treatment -- Europe Drugs -- Law and legislation -- Decision making Medical care -- Cost control -- Europe Medical care -- Cost control |
Issue Date: | 2021 |
Publisher: | Informa |
Citation: | Godman, B., Hill, A., Simoens, S., Selke, G., Selke Krulichová, I., Zampirolli Dias, C., ... & Hill, R. (2021). Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics & Outcomes Research, 21(4), 527-540. |
Abstract: | Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/94434 |
Appears in Collections: | Scholarly Works - FacHScHSM |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Potential_approaches_for_the_pricing_of_cancer_medicines_across_Europe_to_enhance_the_sustainability_of_healthcare_systems_and_the_implications(2021).pdf | 965.86 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.